Kenneth W. Walker

Kenneth W. Walker

Auto-generated profile, based on publicly available information

Kenneth W. Walker

Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, U.S.A

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YXYumei Xiong
Yumei Xiong
KWKenneth Walker
Kenneth Walker
XMXiaoshan Min
Xiaoshan Min
CHClarence Hale
Clarence Hale
TTThanhvien Tran
Thanhvien Tran
MVMurielle M. Véniant
Murielle M. Véniant
Engineered long-acting GDF15-Fc fusion molecules reduce food intake and body weight and improve metabolic profiles in animal models of obesity.

9 May 2013 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
JXJing Xu
Jing Xu
JBJeanine Bussiere
Jeanine Bussiere
JYJunming Yie
Junming Yie
ASAllen Sickmier
Allen Sickmier
PAPhil An
Phil An
KWKenneth W. Walker
Kenneth W. Walker

1 May 2014 in Journal of Chromatography A
Verified
Journal Article
Closed access
DYDaniel Yoo
Daniel Yoo
JPJustin Provchy
Justin Provchy
CPCynthia Park
Cynthia Park
CSCraig Schulz
Craig Schulz
KWKenneth Walker
Kenneth Walker

1 December 2015 in Journal of Chromatography A
Verified
Journal Article
Closed access
DWDwight Winters
Dwight Winters
CCCarolyn Chu
Carolyn Chu
KWKenneth Walker
Kenneth Walker

23 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KWKenneth W Walker
Kenneth W Walker
HSHossein Salimi-Moosavi
Hossein Salimi-Moosavi
GAGregory E Arnold
Gregory E Arnold
QCQing Chen
Qing Chen
MSMarcus Soto
Marcus Soto
JHJohn Hui
John Hui
In this study we compared the pharmacokinetic profile of four unrelated antibodies, which do not bind to mammalian antigens, in IgG1 and IgG2 frameworks in both rats and non-human primates (NHP). This allowed for extensive cross comparison of the impact of antibody isotype, complementarity determining regions (CDR) and model species on pharmacokinetics without the confounding influence of antigen binding in the hosts. While antibody isotype had no significant impact on the pharmacokinetics, the CDRs do alter the profile, and there is an inverse correlation between the neonatal Fc receptor (FcRn) affinity and pharmacokinetic performance. Faster clearance rates were also associated with higher isoelectric points; however, although this panel of antibodies all possess basic isoelectric points, ranging from 8.44 to 9.18, they also have exceptional in vivo half-lives, averaging 369 hours, and low clearance rates, averaging 0.18 ml/h/kg in NHPs. This pattern of pharmacokinetic characteristics was conserved between rats and NHPs.

1 January 2020 in Protein Expression and Purification
Verified
Journal Article
Closed access
DWDwight Winters
Dwight Winters
MTMai Tran
Mai Tran
DYDaniel Yoo
Daniel Yoo
KWKenneth W. Walker
Kenneth W. Walker